Developing a first-in-class small molecule drug for inflammatory disease
European Pharmaceutical Review
NOVEMBER 9, 2023
MyMD plans to present the data to the US Food and Drug Administration (FDA) and intends to advance the clinical programme for MYMD-1 into Phase III either alone or through partnership. There are no FDA-approved medications to treat sarcopenia. Why is a TNF-α inhibitor promising as a first-in-class therapeutic for sarcopenia/frailty?
106 
Let's personalize your content